P-UK Proposal April 2024
Introduction
CarefulAI is delighted to present this proposal to Psychiatry-UK. It aims to harness the power of artificial intelligence to revolutionise the development and regulation compliance of psychiatric AI-enabled products. Our advisory services, supported by sophisticated AI Agents and the PRIDAR process, will empower Psychiatry-UK to make strategic decisions efficiently and effectively, accelerating product innovation while ensuring compliance with UK and international regulatory standards.
Understanding Psychiatry-UK's Needs
Psychiatry-UK has established itself as a leader in providing comprehensive psychiatric services online. It has recognised the need to develop AI-augmented services to continue this trajectory of innovation and excellence and meet demand. Navigating the complex landscape of changing customs and practices with AI and meeting regulatory requirements efficiently is critical.
Solution Overview: AI Agents, the PRIDAR Process and Advisory Services
Our proposal is centred around three components:
1. AI Agents from CarefulAI:
These AI tools are designed to assist in automating and optimising several functions, including user-centred design (e.g. Mo and Emo), product specification (e.g. MoSCoW, and Sona), managing the human resource implications (e.g. Pip), compliance management (e.g. Di and AutoDeclare), preparation for regulatory changes (e.g. Reg and Stan), developing new markets for AI enables service (e.g. Strat, Nova), and pitching for public or private funding (e.g. Innov and Neil).
These agents are adaptable to various company and regulatory environments, making them ideal for companies like Psychiatry-UK. This process will be scalable to speed up the design and development validation process.
2. PRIDAR Process:
PRIDAR (Prioritization of Research, Innovation, Development, Analysis, and Review) is a strategic process that uses AI-agent output to make informed decisions about product development pipelines. This process helps identify the most promising products to develop based on deep data insights from AI Agents. PRIDAR is recognised in BS 30440 as a key process of managing safe, impactful healthcare AI developments. When linked to CarefulAI agents output, it gathers data that aligns with all existing software-as-a-medical devices standards and current and expected AI regulations in the UK and overseas.
3. Advisory Services
CarefulAI understands the opportunities and threats facing Psychiatry-UK, is familiar with the strengths and weaknesses of the AI development team, has mentored team members, and has previously demonstrated the value of PRIDAR in prioritising projects. It is also familiar with the challenges of designing, developing and implementing AI in a mental health setting. Its Chair, Professor Joseph Connor, is also the Chair of the committee that designed and maintains BS30440 - The standard for validating AI in Healthcare. He was also the CTO of Healthy London Partnership, a Pan-London NHS Agency responsible for the design and implementation of AI in mental health services. Before which he was the Director for AI Innovation in NHSE. He is, therefore, in an excellent position to support AI product development process within Psychiatry-UK.
Implementation Plan
Phase 1: Configure AI Agents to align with Psychiatry-UK’s existing IT infrastructure, customs and practice.
Phase 2: Implement the PRIDAR process with training sessions for key staff to ensure the smooth adoption of an optimised AI product development strategy in line with AI Agent Inputs.
Phase 3: Automate the generation of compliance documentation using AI Agents.
Expected Outcomes
By integrating CarefulAI’s tools and the PRIDAR process, Psychiatry-UK can expect:
- Focused Market Driven Innovation: AI-driven insights to strategically prioritise AI product development efforts in a scalable manner.
- Enhanced Efficiency: Reduced time and resources spent on product validation, regulatory compliance and documentation.
Budget and Timeline
The process is expected to take six months, with the following estimated budget breakdown:
- Advisory support: £24,000 plus VAT
- Implementation of CarefulAI Agents in support of Advisory support: £24,000 plus VAT
- Annual Licensing and Maintenance of AI Agents to align with your organisation & country information & intellectual property governance requirements: £8,000 plus VAT/year/per agent after the project- as required.
Conclusion
With CarefulAI’s Advisory Service, AI Agents and the strategic application of the PRIDAR process, Psychiatry-UK will be well-equipped to lead the development of innovative AI products built with that are compliant with global regulatory standards. We are excited about the possibility of partnering with Psychiatry-UK and are confident that our solutions will provide significant value to your endeavours.
Next Steps
We would be pleased to discuss this proposal in more detail and arrange a demonstration of our AI Agents.
CarefulAI is delighted to present this proposal to Psychiatry-UK. It aims to harness the power of artificial intelligence to revolutionise the development and regulation compliance of psychiatric AI-enabled products. Our advisory services, supported by sophisticated AI Agents and the PRIDAR process, will empower Psychiatry-UK to make strategic decisions efficiently and effectively, accelerating product innovation while ensuring compliance with UK and international regulatory standards.
Understanding Psychiatry-UK's Needs
Psychiatry-UK has established itself as a leader in providing comprehensive psychiatric services online. It has recognised the need to develop AI-augmented services to continue this trajectory of innovation and excellence and meet demand. Navigating the complex landscape of changing customs and practices with AI and meeting regulatory requirements efficiently is critical.
Solution Overview: AI Agents, the PRIDAR Process and Advisory Services
Our proposal is centred around three components:
1. AI Agents from CarefulAI:
These AI tools are designed to assist in automating and optimising several functions, including user-centred design (e.g. Mo and Emo), product specification (e.g. MoSCoW, and Sona), managing the human resource implications (e.g. Pip), compliance management (e.g. Di and AutoDeclare), preparation for regulatory changes (e.g. Reg and Stan), developing new markets for AI enables service (e.g. Strat, Nova), and pitching for public or private funding (e.g. Innov and Neil).
These agents are adaptable to various company and regulatory environments, making them ideal for companies like Psychiatry-UK. This process will be scalable to speed up the design and development validation process.
2. PRIDAR Process:
PRIDAR (Prioritization of Research, Innovation, Development, Analysis, and Review) is a strategic process that uses AI-agent output to make informed decisions about product development pipelines. This process helps identify the most promising products to develop based on deep data insights from AI Agents. PRIDAR is recognised in BS 30440 as a key process of managing safe, impactful healthcare AI developments. When linked to CarefulAI agents output, it gathers data that aligns with all existing software-as-a-medical devices standards and current and expected AI regulations in the UK and overseas.
3. Advisory Services
CarefulAI understands the opportunities and threats facing Psychiatry-UK, is familiar with the strengths and weaknesses of the AI development team, has mentored team members, and has previously demonstrated the value of PRIDAR in prioritising projects. It is also familiar with the challenges of designing, developing and implementing AI in a mental health setting. Its Chair, Professor Joseph Connor, is also the Chair of the committee that designed and maintains BS30440 - The standard for validating AI in Healthcare. He was also the CTO of Healthy London Partnership, a Pan-London NHS Agency responsible for the design and implementation of AI in mental health services. Before which he was the Director for AI Innovation in NHSE. He is, therefore, in an excellent position to support AI product development process within Psychiatry-UK.
Implementation Plan
Phase 1: Configure AI Agents to align with Psychiatry-UK’s existing IT infrastructure, customs and practice.
Phase 2: Implement the PRIDAR process with training sessions for key staff to ensure the smooth adoption of an optimised AI product development strategy in line with AI Agent Inputs.
Phase 3: Automate the generation of compliance documentation using AI Agents.
Expected Outcomes
By integrating CarefulAI’s tools and the PRIDAR process, Psychiatry-UK can expect:
- Focused Market Driven Innovation: AI-driven insights to strategically prioritise AI product development efforts in a scalable manner.
- Enhanced Efficiency: Reduced time and resources spent on product validation, regulatory compliance and documentation.
Budget and Timeline
The process is expected to take six months, with the following estimated budget breakdown:
- Advisory support: £24,000 plus VAT
- Implementation of CarefulAI Agents in support of Advisory support: £24,000 plus VAT
- Annual Licensing and Maintenance of AI Agents to align with your organisation & country information & intellectual property governance requirements: £8,000 plus VAT/year/per agent after the project- as required.
Conclusion
With CarefulAI’s Advisory Service, AI Agents and the strategic application of the PRIDAR process, Psychiatry-UK will be well-equipped to lead the development of innovative AI products built with that are compliant with global regulatory standards. We are excited about the possibility of partnering with Psychiatry-UK and are confident that our solutions will provide significant value to your endeavours.
Next Steps
We would be pleased to discuss this proposal in more detail and arrange a demonstration of our AI Agents.